Home › Trials › NCT05050955

Evaluating LungCare for lung transplant recipients

AlloSure Lung Assessment and Metagenomics Outcomes Study

CareDx · NCT05050955

This study is testing if a new monitoring system called LungCare can help lung transplant recipients detect rejection and infections better during their regular check-ups.

Quick facts

Study typeObservational
Enrollment550 (estimated)
Ages18 Years and up
SexAll
SponsorCareDx (industry)
Locations22 sites (Birmingham, Alabama and 21 other locations)
Trial IDNCT05050955 on ClinicalTrials.gov

What this trial studies

This observational study, known as ALAMO, is a prospective registry that focuses on lung transplant recipients who are undergoing surveillance testing with LungCare, which includes AlloSure-Lung, AlloMap Lung, and HistoMap. The study aims to assess the effectiveness of AlloSure Lung in detecting various types of rejection and infections in lung transplant patients. Participants will be recruited during routine care visits and will have their clinical outcomes and treatment data collected from medical records. The study's design allows for real-world evaluation of LungCare's performance in managing lung transplant recipients.

Who should consider this trial

Good fit: Ideal candidates for this study are lung transplant recipients who are within 90 days post-transplant and have initiated LungCare surveillance testing.

Not a fit: Patients who have undergone multi-organ transplants, are pregnant, or have active malignancies may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could improve the monitoring and management of lung transplant recipients, potentially reducing complications and improving patient outcomes.

How similar studies have performed: Other studies have shown promise in using similar surveillance approaches for transplant recipients, indicating potential for success in this study.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Unilateral or Bilateral, deceased-donor, initial or re-transplant
2. ≤ 90 days post-transplant
3. Ability to understand and provide informed consent and adhere to laboratory surveillance schedule
4. Patients who have LungCare initiated within 30 days of signing the informed consent form

Exclusion Criteria:

1. Multi-organ transplants
2. Pregnancy
3. Active malignancy

Where this trial is running

Birmingham, Alabama and 21 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Lung Transplant Infection, Lung Transplant, Complications, Lung Transplant Failure and Rejection

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.